Vikram G Shakkottai

List of Publications by Year
in descending order

68	3,890	159585 30	138484 58
papers	citations	h-index	g-index

75	75	75	4651
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Polyglutamine spinocerebellar ataxias â€" from genes to potential treatments. Nature Reviews Neuroscience, 2017, 18, 613-626.	10.2	270
2	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
3	Early Changes in Cerebellar Physiology Accompany Motor Dysfunction in the Polyglutamine Disease Spinocerebellar Ataxia Type 3. Journal of Neuroscience, 2011, 31, 13002-13014.	3.6	190
4	Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications. Current Medicinal Chemistry, 2007, 14, 1437-1457.	2.4	189
5	Polyglutamine Repeats in Neurodegenerative Diseases. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 1-27.	22.4	189
6	Current Opinions and Areas of Consensus on the Role of the Cerebellum in Dystonia. Cerebellum, 2017, 16, 577-594.	2.5	184
7	Mutations in KCND3 cause spinocerebellar ataxia type 22. Annals of Neurology, 2012, 72, 859-869.	5.3	138
8	Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice. Annals of Neurology, 2018, 84, 64-77.	5.3	127
9	Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Human Molecular Genetics, 2010, 19, 837-847.	2.9	123
10	Mutations in VPS13D lead to a new recessive ataxia with spasticity and mitochondrial defects. Annals of Neurology, 2018, 83, 1075-1088.	5.3	122
11	Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet Journal of Rare Diseases, 2013, 8, 177.	2.7	117
12	SKCa Channels Mediate the Medium But Not the Slow Calcium-Activated Afterhyperpolarization in Cortical Neurons. Journal of Neuroscience, 2004, 24, 3537-3542.	3.6	113
13	FGF14 regulates the intrinsic excitability of cerebellar Purkinje neurons. Neurobiology of Disease, 2009, 33, 81-88.	4.4	112
14	Design and Characterization of a Highly Selective Peptide Inhibitor of the Small Conductance Calcium-activated K+Channel, SkCa2. Journal of Biological Chemistry, 2001, 276, 43145-43151.	3.4	106
15	Toward RNAi Therapy for the Polyglutamine Disease Machadoâ€"Joseph Disease. Molecular Therapy, 2013, 21, 1898-1908.	8.2	102
16	Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. Journal of Clinical Investigation, 2004, 113, 582-590.	8.2	94
17	Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability. Journal of Neuroscience, 2015, 35, 11292-11307.	3.6	93
18	Depression and clinical progression in spinocerebellar ataxias. Parkinsonism and Related Disorders, 2016, 22, 87-92.	2.2	85

#	ARTICLE	IF	CITATIONS
19	Coordinate regulation of mutant NPC1 degradation by selective ER autophagy and MARCH6-dependent ERAD. Nature Communications, 2018, 9, 3671.	12.8	82
20	Clinical Neurogenetics. Neurologic Clinics, 2013, 31, 987-1007.	1.8	78
21	Targeted exome analysis identifies the genetic basis of disease in over 50% of patients with a wide range of ataxia-related phenotypes. Genetics in Medicine, 2019, 21, 195-206.	2.4	65
22	Nicotinamide Pathway-Dependent Sirt1 Activation Restores Calcium Homeostasis to Achieve Neuroprotection in Spinocerebellar Ataxia Type 7. Neuron, 2020, 105, 630-644.e9.	8.1	63
23	Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. Journal of Clinical Investigation, 2004, 113, 582-590.	8.2	60
24	Potassium channel dysfunction underlies Purkinje neuron spiking abnormalities in spinocerebellar ataxia type 2. Human Molecular Genetics, 2017, 26, 3935-3945.	2.9	54
25	Temporal and cell-specific deletion establishes that neuronal Npc1 deficiency is sufficient to mediate neurodegeneration. Human Molecular Genetics, 2011, 20, 4440-4451.	2.9	53
26	Ion channel dysfunction in cerebellar ataxia. Neuroscience Letters, 2019, 688, 41-48.	2.1	52
27	Targeting potassium channels to treat cerebellar ataxia. Annals of Clinical and Translational Neurology, 2018, 5, 297-314.	3.7	50
28	The Initial Symptom and Motor Progression in Spinocerebellar Ataxias. Cerebellum, 2017, 16, 615-622.	2.5	42
29	Dystonia and ataxia progression in spinocerebellar ataxias. Parkinsonism and Related Disorders, 2017, 45, 75-80.	2.2	39
30	Coenzyme Q10 and spinocerebellar ataxias. Movement Disorders, 2015, 30, 214-220.	3.9	36
31	Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic stem cell line. Stem Cell Research, 2019, 39, 101504.	0.7	35
32	SK3-1C, a Dominant-negative Suppressor of SKCa and IKCa Channels. Journal of Biological Chemistry, 2004, 279, 6893-6904.	3.4	34
33	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Translational Medicine, 2020, 12, .	12.4	32
34	Protein kinase C activity is a protective modifier of Purkinje neuron degeneration in cerebellar ataxia. Human Molecular Genetics, 2018, 27, 1396-1410.	2.9	30
35	Autosomal-dominant cerebellar ataxias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 147, 173-185.	1.8	29
36	Translating cerebellar Purkinje neuron physiology to progress in dominantly inherited ataxia. Future Neurology, 2014, 9, 187-196.	0.5	27

#	Article	IF	Citations
37	Physiologic Alterations in Ataxia. Archives of Neurology, 2009, 66, 1196-201.	4.5	25
38	A Chlorzoxazoneâ€Baclofen Combination Improves Cerebellar Impairment in Spinocerebellar Ataxia Type 1. Movement Disorders, 2021, 36, 622-631.	3.9	25
39	COQ4 Mutation Leads to Childhood-Onset Ataxia Improved by CoQ10 Administration. Cerebellum, 2019, 18, 665-669.	2.5	24
40	Single amino acid deletion in transmembrane segment D4S6 of sodium channel Scn8a (Nav1.6) in a mouse mutant with a chronic movement disorder. Neurobiology of Disease, 2016, 89, 36-45.	4.4	23
41	In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3. Movement Disorders, 2020, 35, 1774-1786.	3.9	23
42	The Role for Alterations in Neuronal Activity in the Pathogenesis of Polyglutamine Repeat Disorders. Neurotherapeutics, 2014, 11, 751-763.	4.4	22
43	Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease. Annals of Translational Medicine, 2016, 4, 25.	1.7	22
44	Physiologic Changes Associated with Cerebellar Dystonia. Cerebellum, 2014, 13, 637-644.	2.5	21
45	Dendritic potassium channel dysfunction may contribute to dendrite degeneration in spinocerebellar ataxia type 1. PLoS ONE, 2018, 13, e0198040.	2.5	21
46	Alterations in cerebellar physiology are associated with a stiff-legged gait in Atcayji-hes mice. Neurobiology of Disease, 2014, 67, 140-148.	4.4	20
47	MTSS1/Src family kinase dysregulation underlies multiple inherited ataxias. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12407-E12416.	7.1	20
48	Altered Capicua expression drives regional Purkinje neuron vulnerability through ion channel gene dysregulation in spinocerebellar ataxia type 1. Human Molecular Genetics, 2020, 29, 3249-3265.	2.9	20
49	Synthetic high-density lipoprotein nanoparticles for the treatment of Niemannâ€“Pick diseases. BMC Medicine, 2019, 17, 200.	5.5	19
50	Heat Shock Protein Beta-1 Modifies Anterior to Posterior Purkinje Cell Vulnerability in a Mouse Model of Niemann-Pick Type C Disease. PLoS Genetics, 2016, 12, e1006042.	3.5	18
51	Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channelâ€“Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3. Cerebellum, 2021, 20, 41-53.	2.5	17
52	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	7.6	17
53	Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor. Cerebellum, 2019, 18, 519-526.	2.5	16
54	The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3. Parkinsonism and Related Disorders, 2020, 72, 37-43.	2.2	16

#	ARTICLE	IF	CITATIONS
55	Alanyl-tRNA Synthetase 2 (AARS2)-Related Ataxia Without Leukoencephalopathy. Cerebellum, 2020, 19, 154-160.	2.5	15
56	Generation of Spinocerebellar Ataxia Type 2 induced pluripotent stem cell lines, CHOPi002-A and CHOPi003-A, from patients with abnormal CAG repeats in the coding region of the ATXN2 gene. Stem Cell Research, 2019, 34, 101361.	0.7	13
57	Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias. Tremor and Other Hyperkinetic Movements, 2017, 7, 492.	2.0	13
58	Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials. Neurotherapeutics, 2019, 16, 999-1008.	4.4	9
59	Discovery of Novel Activators of Large-Conductance Calcium-Activated Potassium Channels for the Treatment of Cerebellar Ataxia. Molecular Pharmacology, 2022, 102, 17-28.	2.3	9
60	THAP1 modulates oligodendrocyte maturation by regulating ECM degradation in lysosomes. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	7
61	Expanding the genetic basis of ataxia. Nature Genetics, 2019, 51, 580-581.	21.4	5
62	Vascular risk factors and clinical progression in spinocerebellar ataxias. Tremor and Other Hyperkinetic Movements, 2015, 5, 287.	2.0	5
63	C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias. Movement Disorders, 2018, 33, 497-498.	3.9	4
64	Dysphagia in spinocerebellar ataxias type 1, 2, 3 and 6. Journal of the Neurological Sciences, 2020, 415, 116878.	0.6	3
65	Multiple system atrophy pathology is associated with primary SjÃ¶grenâ€™s syndrome. JCI Insight, 2020, 5, .	5.0	3
66	Preliminary Study of Vibrotactile Feedback during Home-Based Balance and Coordination Training in Individuals with Cerebellar Ataxia. Sensors, 2022, 22, 3512.	3.8	2
67	Vulnerability of Human Cerebellar Neurons to Degeneration in Ataxia-Causing Channelopathies. Frontiers in Systems Neuroscience, 0, 16, .	2.5	1
68	The inherited ataxias. , 2020, , 75-97.		0